In buprenorphine-naloxone formulations, what is the purpose of including naloxone?

In buprenorphine-naloxone formulations, what is the purpose of including naloxone?

• A. It enhances the analgesic effect when taken orally.
• B. It deters misuse by injection, since naloxone is poorly absorbed sublingually but active if injected.
• C. It increases the half-life of buprenorphine.
• D. It blocks NMDA receptors to reduce cravings.

Answer: (B)

The key idea is misuse deterrence. In these formulations, naloxone is included so that if the product is used as directed (sublingually), naloxone has very poor absorption through the mouth and won’t block buprenorphine or cause withdrawal. But if someone tries to misuse it by injecting the medication, the naloxone is rapidly absorbed and acts as an opioid receptor antagonist, which can precipitate withdrawal in someone who is opioid-dependent. This makes injection less appealing and helps prevent abuse. Other possibilities don’t fit the intended purpose: taking it orally wouldn’t meaningfully enhance analgesia or duration, naloxone doesn’t increase buprenorphine’s half-life, and it doesn’t act by blocking NMDA receptors to reduce cravings.

The key idea is misuse deterrence. In these formulations, naloxone is included so that if the product is used as directed (sublingually), naloxone has very poor absorption through the mouth and won’t block buprenorphine or cause withdrawal. But if someone tries to misuse it by injecting the medication, the naloxone is rapidly absorbed and acts as an opioid receptor antagonist, which can precipitate withdrawal in someone who is opioid-dependent. This makes injection less appealing and helps prevent abuse.

Other possibilities don’t fit the intended purpose: taking it orally wouldn’t meaningfully enhance analgesia or duration, naloxone doesn’t increase buprenorphine’s half-life, and it doesn’t act by blocking NMDA receptors to reduce cravings.